Biodexa Pharmaceuticals PLC
BDRX0.920USD
+0.054+6.22%
Fechamento 06/23, 16:00（ET）Cotações atrasadas em 15 min
6.15BValor de mercado
--P/L TTM
Mais detalhes de Biodexa Pharmaceuticals PLC Empresa
Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.
Informações da empresa
Código da empresaBDRX
Nome da EmpresaBiodexa Pharmaceuticals PLC
Data de listagemDec 08, 2014
Fundado em2014
CEOMr. Stephen A. Stamp
Número de funcionários- -
Tipo de títulosDepository Receipt
Fim do ano fiscalDec 08
Endereço1 Caspian Point
CidadeABINGDON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited Kingdom
Código postalCF10 4DQ
Telefone4401235888300
Sitehttps://www.biodexapharma.com/
Código da empresaBDRX
Data de listagemDec 08, 2014
Fundado em2014
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director, Secretary
Chief Executive Officer, Chief Financial Officer, Executive Director, Secretary
--
--
Dr. Sijmen (Sijmen) De Vries, M.D.
Dr. Sijmen (Sijmen) De Vries, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Stephen Barry Parker
Dr. Stephen Barry Parker
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Controller
Group Controller
--
--
Dr. Gary A. Shangold, M.D.
Dr. Gary A. Shangold, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Steve Ellul
Mr. Steve Ellul
Chief Business Officer
Chief Business Officer
--
--
Mr. Dmitry Zamoryakhin, M.D.
Mr. Dmitry Zamoryakhin, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
--
--
Ms. Nicola Tuckwell
Ms. Nicola Tuckwell
Vice President, Head of Clinical Operations
Vice President, Head of Clinical Operations
--
--
Ms. Ann Merchant
Ms. Ann Merchant
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director, Secretary
Chief Executive Officer, Chief Financial Officer, Executive Director, Secretary
--
--
Dr. Sijmen (Sijmen) De Vries, M.D.
Dr. Sijmen (Sijmen) De Vries, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Stephen Barry Parker
Dr. Stephen Barry Parker
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Controller
Group Controller
--
--
Dr. Gary A. Shangold, M.D.
Dr. Gary A. Shangold, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Detalhamento da receita
Moeda: GBPAtualizado em: dom, 6 de abr
Moeda: GBPAtualizado em: dom, 6 de abr
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Sem dados
Por RegiãoGBP
Nome
Receita
Proporção
Belgium
381.00K
100.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: seg, 2 de jun
Atualizado em: seg, 2 de jun
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Cavalry Fund I Management, LLC
3.47%
Brio Capital Management LLC
3.32%
Abbe (Richard)
0.48%
Bukwang Pharmaceutical Co., Ltd.
0.28%
Melior Pharmaceuticals I, Inc.
0.28%
Other
92.17%
Investidores
Investidores
Proporção
Cavalry Fund I Management, LLC
3.47%
Brio Capital Management LLC
3.32%
Abbe (Richard)
0.48%
Bukwang Pharmaceutical Co., Ltd.
0.28%
Melior Pharmaceuticals I, Inc.
0.28%
Other
92.17%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
6.82%
Corporation
0.69%
Individual Investor
0.48%
Investment Advisor
0.46%
Bank and Trust
0.20%
Venture Capital
0.11%
Hedge Fund
0.10%
Research Firm
0.01%
Other
91.13%
Participação acionária institucional
Atualizado em: sáb, 22 de fev
Atualizado em: sáb, 22 de fev
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
37
260.22K
10.16%
+146.72K
2024Q4
37
258.63K
38.68%
+145.03K
2024Q3
39
166.61K
38.54%
+138.41K
2024Q2
36
78.92K
24.69%
+69.19K
2024Q1
28
31.04K
21.44%
+27.53K
2023Q4
30
32.82K
23.15%
+31.84K
2023Q3
21
574.00
6.29%
-2.15K
2023Q2
21
425.00
5.59%
-1.99K
2023Q1
22
183.00
8.18%
-2.20K
2022Q4
21
54.00
9.96%
+24.00
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Brio Capital Management LLC
167.68K
25.08%
+110.57K
+193.59%
Nov 14, 2024
Abbe (Richard)
24.34K
3.64%
+24.34K
--
Jul 19, 2024
Bukwang Pharmaceutical Co., Ltd.
14.18K
2.12%
+14.18K
--
Apr 01, 2024
Melior Pharmaceuticals I, Inc.
14.18K
2.12%
+14.18K
--
Apr 01, 2024
Mercer Street Capital Partners, LLC
14.18K
2.12%
+7.93K
+126.83%
Apr 01, 2024
UBS Financial Services, Inc.
7.05K
1.05%
-3.17K
-31.03%
Dec 31, 2024
GS Capital Partners LLC
6.31K
0.94%
+6.31K
--
Apr 01, 2024
Ionic Ventures LLC
5.42K
0.81%
+5.33K
+5.92K%
Dec 31, 2023
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sep 19, 2024
Merger
25<1
Sep 19, 2024
Merger
25<1
Sep 19, 2024
Merger
25<1
Sep 19, 2024
Merger
25<1
Jun 26, 2023
Merger
80<1
Jun 26, 2023
Merger
80<1
Data
Tipo
Proporção
Sep 19, 2024
Merger
25<1
Sep 19, 2024
Merger
25<1
Sep 19, 2024
Merger
25<1
Sep 19, 2024
Merger
25<1
Jun 26, 2023
Merger
80<1
Jun 26, 2023
Merger
80<1
Jun 26, 2023
Merger
80<1
Jun 26, 2023
Merger
80<1
Mar 16, 2023
Merger
4<1
Mar 16, 2023
Merger
4<1
Ver Mais
